US28176E1082
© BusinessWire
04.12.2025
EW
LISTED
NYSE
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
News Preview
Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), m...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2025
EW
LISTED
NYSE
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
News Preview
Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many dri...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
EW
LISTED
NYSE
Edwards Lifesciences Announces CFO Transition Plan
News Preview
Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company’s chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment o...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
30.10.2025
EW
LISTED
NYSE
Edwards Lifesciences Reports Third Quarter Results
News Preview
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025.
Recent Highlights
Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups
Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6%
Q3 TMTT sales of $145.2 million, growth driven by PAS...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
28.10.2025
EW
LISTED
NYSE
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.
If you currently own Edwards stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back t...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
EW
LISTED
NYSE
Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
News Preview
Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-d...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
EW
LISTED
NYSE
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
News Preview
Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
EW
LISTED
NYSE
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
News Preview
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
EW
LISTED
NYSE
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
News Preview
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).
If you currently own shares of Edwards stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=29704 for more informati...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
EW
LISTED
NYSE
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
News Preview
Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).
If you currently own shares of Edwards stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. Y...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
EW
LISTED
NYSE
Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
News Preview
Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless of symptoms.
The guidelines enable a proactive approach to disease management and underscore that intervention should be considered for asymptomat...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2025
EW
LISTED
NYSE
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
News Preview
Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025.
Under the terms of this ASR, Edwards will receive an initial delivery of approximately...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.07.2025
EW
LISTED
NYSE
Edwards Lifesciences Reports Second Quarter Results
News Preview
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025.
Recent Highlights
Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups
Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8%
Q2 TMTT sales reached $134.5 million or $133.0 million adjus...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
EW
LISTED
NYSE
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025
News Preview
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be avail...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
EW
LISTED
NYSE
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
News Preview
Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease.
The results of a new real-world study of more than 24,000 patients demonstrated that intervening on t...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
EW
LISTED
NYSE
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
News Preview
Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.
Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
EW
LISTED
NYSE
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
News Preview
Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
Approval of the SAPIEN 3 platfo...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
EW
LISTED
NYSE
Edwards Lifesciences Reports First Quarter Results
News Preview
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025.
Recent Highlights
Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1
Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected
Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growt...
Themefolio
Profiler
Peergroup
© BusinessWire
18.04.2025
EW
LISTED
NYSE
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue
News Preview
Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.
For more than 65 years, Edwards has been the leader in...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
EW
LISTED
NYSE
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
News Preview
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be ava...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
EW
LISTED
NYSE
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System
News Preview
Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
EW
LISTED
NYSE
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
News Preview
Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease.
Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) ma...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
EW
LISTED
NYSE
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
News Preview
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.
Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
EW
LISTED
NYSE
Edwards Lifesciences Reports Fourth Quarter Results
News Preview
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.
Highlights and Outlook
Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups
Q4 TAVR sales grew 6%; constant currency2 sales grew 5%
Q4 TMTT sales grew 88% to $105 million with i...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
EW
LISTED
NYSE
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW).
On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
EW
LISTED
NYSE
Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025
News Preview
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also b...
Themefolio
Profiler
Peergroup
© BusinessWire
25.01.2025
EW
LISTED
NYSE
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW).
On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
EW
LISTED
NYSE
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025.
Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
EW
LISTED
NYSE
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation (“Edwards” or the “Company”) (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
EW
LISTED
NYSE
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Edwards Lifesciences Corporation (EW)
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Clas...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
EW
LISTED
NYSE
EW Deadline: Rosen Law Firm Urges Edwards Lifesciences Corporation (NYSE: EW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024. Edwards describes itself as an “international company that researches, develops, provides products and tech...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
EW
LISTED
NYSE
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
News Preview
Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a s...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
EW
LISTED
NYSE
Lead Plaintiff Deadline on December 13, 2024 for EW Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
EW
LISTED
NYSE
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
News Preview
Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
An analysis of data from mo...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
EW
LISTED
NYSE
Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation
News Preview
Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease.
“The data at TCT on Edwards’ innovations underscore our commitment to sci...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
EW
LISTED
NYSE
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
News Preview
Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) s...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
EW
LISTED
NYSE
Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
News Preview
Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomat...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2024
EW
LISTED
NYSE
EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Edwards Lifesciences Corporation Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards” or “the Company”) (NYSE: EW) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
EW
LISTED
NYSE
Edwards Lifesciences Reports Third Quarter Results
News Preview
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024.
Highlights and Outlook
Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10%
Q3 TAVR sales grew 6%; constant currency1 sales grew 7%
TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress w...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
EW
LISTED
NYSE
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Edwards Lifesciences Corporation (EW)
News Preview
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
EW
LISTED
NYSE
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Edwards Lifesciences Corporation (EW)
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
EW
LISTED
NYSE
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation (EW) Investors
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”). Edwards Lifescience...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
EW
LISTED
NYSE
EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the “Class Period”), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action laws...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
EW
LISTED
NYSE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation (EW) Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
EW
LISTED
NYSE
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation (EW) Investors
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”). Edwards Lifesciences Corporation investors have until D...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
EW
LISTED
NYSE
EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Edwards Lifesciences Corporation Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards” or “the Company”) (NYSE: EW) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
EW
LISTED
NYSE
Edwards Lifesciences to Host Earnings Conference Call on October 24, 2024
News Preview
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
EW
LISTED
NYSE
Edwards Lifesciences Corporation (EW) Investors: December 13, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
EW
LISTED
NYSE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Edwards Lifesciences Corporation (EW) on Behalf of Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
EW
LISTED
NYSE
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Edwards Lifesciences Corporation (EW) on Behalf of Investors
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) investors concerning the Company’s possible violations of federal securities laws.
On July 24, 2024, Edwards Lifesciences announced fiscal second quarter 2024 results which came in below expe...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
EW
LISTED
NYSE
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation (“Edwards Lifesciences” or “the Company”) (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exc...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
EW
LISTED
NYSE
The Law Offices of Frank R. Cruz Announces Investigation of Edwards Lifesciences Corporation (EW) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On July 24, 2024, Edwards Lif...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
EW
LISTED
NYSE
Rosen Law Firm Urges Edwards Lifesciences Corporation (NYSE: EW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024. Edwards describes itself as an “international company that researches, develops, provides products and technologies...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
EW
LISTED
NYSE
EW INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captio...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
EW
LISTED
NYSE
EIN-JAHRES-DATEN ZEIGEN HERVORRAGENDE ERGEBNISSE FÜR DAS CORDELLA PULMONALARTERIEN-SENSORSYSTEM VON ENDOTRONIX
News Preview
NAPERVILLE, Illinois, 30. September 2024 /PRNewswire/ -- Endotronix, ein Unternehmen von Edwards Lifesciences (NYSE: EW), gab heute die klinischen Ein-Jahres-Ergebnisse der PROACTIVE-HF-Studie bekannt, in der die Ergebnisse des Cordella Pulmonalarterien (PA)-Sensorsystems ausgewertet wurden. Die Daten wurden im Rahmen der wissenschaftlichen Jahre...
Themefolio
Profiler
Peergroup
© PR Newswire
28.09.2024
EW
LISTED
NYSE
ONE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR ENDOTRONIX CORDELLA PULMONARY ARTERY SENSOR SYSTEM
News Preview
NAPERVILLE, Ill., Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) Sensor System. The data were shared as part of the Heart Failure Society of America (HFSA) Annual Scientific Meeting....
Themefolio
Profiler
Peergroup
© PR Newswire
28.09.2024
EW
LISTED
NYSE
ONE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR ENDOTRONIX CORDELLA PULMONARY ARTERY SENSOR SYSTEM
News Preview
NAPERVILLE, Ill., Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) Sensor System. The data were shared as part of the Heart Failure Society of America (HFSA) Annual Scientific Meeting....
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
EW
LISTED
NYSE
Edwards Lifesciences Completes Sale of Critical Care
News Preview
Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX) for $4.2 billion in an all-cash transaction. The net proceeds from the sale will be used to fund strategic initiatives including the previously announced acquisitions and share repurchases.
“Cri...
Themefolio
Profiler
Peergroup
© BusinessWire
31.08.2024
EW
LISTED
NYSE
First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
News Preview
Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving...
Themefolio
Profiler
Peergroup
© BusinessWire
31.08.2024
EW
LISTED
NYSE
CORRECTING and REPLACING First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
News Preview
Please replace the release with the following corrected version.
The updated release reads:
FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES
Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving tra...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
